Literature DB >> 10574616

Subcellular localization of interferon-inducible Myc/stat-interacting protein Nmi is regulated by a novel IFP 35 homologous domain.

N D Lee1, J Chen, R L Shpall, L Naumovski.   

Abstract

Nmi was initially identified through a yeast two-hybrid interaction with N-Myc but it also interacts with c-Myc, Max, Fos, and several other transcription factors, including signal transducer and activator of transcription (Stat) proteins. Nmi is an interferon (IFN)-inducible protein with 25% amino acid identity to the IFN-inducible protein IFP 35. We have found that this homology consists of a novel domain of approximately 90-92 amino acids (aa) that is repeated in tandem in each protein. This region, termed Nmi/IFP 35 domain (NID), is important for subcellular localization of Nmi. Full-length Nmi protein or deletion constructs containing a single NID are localized to the cytoplasm, but amino-terminal Nmi fragments of up to 92 aa containing neither NID are nuclear. Fusion of the amino-terminal end of Nmi to pyruvate kinase, an exclusively cytoplasmic protein, results in a cytoplasmic fusion protein, suggesting that the amino-terminal end of Nmi does not contain a classic nuclear localization signal (NLS). Fusion of the amino-terminal end of Nmi to green fluorescent protein (GFP), which is normally found in both nuclear and cytoplasmic compartments, does not alter GFP distribution, whereas fusion of a single NID to GFP targets the fusion to the cytoplasm. Fusion of a nuclear localization signal (NLS) to full-length Nmi or NID repeats targets the hybrid to the nucleus, suggesting that a strong NLS is dominant to the cytoplasmic localization function of NID. NID may mediate cytoplasmic localization of the full-length Nmi protein through NID-NID protein interactions as demonstrated by yeast two-hybrid assay, immunoprecipitation, and the presence of Nmi in a high molecular weight protein complex. These results suggest that Nmi is composed of a modular structure with an amino-terminal domain that when separated from the rest of the protein is nuclear. The carboxy-terminal two thirds of the protein is composed of two NID that mediate cytoplasmic localization of the full-length protein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10574616     DOI: 10.1089/107999099312902

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  6 in total

1.  Stability of Nmi protein is controlled by its association with Tip60.

Authors:  Keman Zhang; Gang Zheng; Yu-Chung Yang
Journal:  Mol Cell Biochem       Date:  2007-04-04       Impact factor: 3.396

2.  N-Myc interactor inhibits prototype foamy virus by sequestering viral Tas protein in the cytoplasm.

Authors:  Xiaomei Hu; Wei Yang; Ruikang Liu; Yunqi Geng; Wentao Qiao; Juan Tan
Journal:  J Virol       Date:  2014-04-09       Impact factor: 5.103

Review 3.  Roles of N-Myc and STAT interactor in cancer: From initiation to dissemination.

Authors:  Hawley C Pruitt; Daniel J Devine; Rajeev S Samant
Journal:  Int J Cancer       Date:  2016-03-11       Impact factor: 7.396

Review 4.  Biological function of Foot-and-mouth disease virus non-structural proteins and non-coding elements.

Authors:  Yuan Gao; Shi-Qi Sun; Hui-Chen Guo
Journal:  Virol J       Date:  2016-06-22       Impact factor: 4.099

5.  Human cytomegalovirus UL23 inhibits transcription of interferon-γ stimulated genes and blocks antiviral interferon-γ responses by interacting with human N-myc interactor protein.

Authors:  Linyuan Feng; Jingxue Sheng; Gia-Phong Vu; Yujun Liu; Chingman Foo; Songbin Wu; Phong Trang; Marco Paliza-Carre; Yanhong Ran; Xiaoping Yang; Xu Sun; Zemin Deng; Tianhong Zhou; Sangwei Lu; Hongjian Li; Fenyong Liu
Journal:  PLoS Pathog       Date:  2018-01-29       Impact factor: 6.823

Review 6.  IFP35 Is a Relevant Factor in Innate Immunity, Multiple Sclerosis, and Other Chronic Inflammatory Diseases: A Review.

Authors:  Roberto De Masi; Stefania Orlando; Francesco Bagordo; Tiziana Grassi
Journal:  Biology (Basel)       Date:  2021-12-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.